APR 9 5 7002 SU

Express Mail No.: <u>EL 477 035 293</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Vournakis et al.

Serial No.: 09/781,182

Group Art Unit: 1614

Filed: February 12, 2001

Examiner: To Be Assigned

For:

COMPOSITIONS AND METHODS FOR Attorney Docket No.: 7867-022-999

MODULATION OF VASCULAR STRUCTURE AND/OR FUNCTION

PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.115

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the Rule 115 of the Rules of Practice, please enter the following amendments and consider the following remarks. Applicants submit herewith:

(1) Exhibit A, a marked up version of the amended paragraph of the specification (2) Exhibit B, a marked up version of the amended claims; (3) Exhibit C, a copy of the claims as they will be pending upon entry of the Preliminary Amendment; (3) an Amendment Fee Transmittal Sheet; (5) an Information Disclosure Statement; and (6) a List of References Cited listing references AA to CH together with a copy of references AA - CH.

IN THE SPECIFICATION:

A marked up version of the following amended paragraph is attached hereto as Appendix A. Matter that has been deleted from the paragraph is indicated by brackets and matter that has been added to the paragraph is indicated by underlining:

Please amend the specification as follows:

On page 72, please replace the paragraph beginning "The procedure was repeated with U-46619" with the following paragraph:

The procedure was repeated with U-46619 followed by p-GlcNAc. p-GlcNAc produced a concentration-dependent vasocontraction from 14 to 140 µg/ml, as indicated in Figure 22. At a developed concentration of 140 µg/ml, p-GlcNAc significantly contracted

09781182

00000017 161150 7.00 CH 2.00 CH

i FC:203

(A)